Market reviews 2010

Market review on human pharmaceuticals 2010

Published 9 February 2011

According to statistics collected by Finnish Pharmaceutical Data, Finnish wholesale of human pharmaceuticals in 2010 totalled EUR 1,926 (1,947) million, slightly down on the previous year.

Finland is the most important individual market for Orion, its share of total net sales declined a little but was still about a quarter of the total net sales. Despite a decline in the market as a whole, Orion was able to increase sales in all areas and strengthen its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data, Orion’s wholesale of pharmaceuticals in Finland in 2010 amounted to EUR 192 (186) million, up by 3% compared with the previous year. Orion’s market share was 10% (10%), which was over three percentage points higher than the second-largest company’s market share.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2010 the total sales of Parkinson’s drugs in the United States were up by 2% at USD 1,005 million (USD 981 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in September totalled EUR 993 (894) million, and the average market growth was 11%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs continued to grow favourably and clearly faster than the market as a whole in the United States and in Japan. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending September 2010, total sales of Orion’s Parkinson’s drugs were up by 6% at USD 181 (171) million in the United States, up by 6% at a total of EUR 156 (147) million in the five largest markets in Europe, and up by 39% at EUR 43 (31) million in Japan. The market share of Orion’s Parkinson’s drugs was 18% in the United States, on average 16% in the five largest European markets and 10% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Precedex® intensive care sedative (dexmedetomidine), which is becoming increasingly important for Orion, were up by 61% at USD 142 million in the 12-month period ending September 2010 (USD 88 million in the previous 12-month period); 86% of the sales amounting to USD 123 (74) million were in the United States, where Precedex® sales grew by 67%

 

Published 26 October 2010

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–September 2010 totalled EUR 1,415 (1,434) million, down by 1% on the comparative period of the previous year. The decrease in the market as a whole was mainly due to price decreases in pharmaceuticals covered by the reference price system. About half of the prescription drug market by volume is covered by the reference price system, which has been in force since the beginning of April 2009.

Finland is the most important individual market for Orion, generating one-quarter of the Group’s net sales. Orion continued to strengthen its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2010 amounted to EUR 141 (137) million, up by 2% on the comparative period of the previous year. Orion’s market share was 10% (10%), which was nearly four percentage points higher than for the second-largest company.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2010 the total sales of all Parkinson’s drugs in the United States were up by 8% at USD 1,029 million (USD 956 million in the previous 12-month period). The five largest European markets for Parkinson’s drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in June totalled EUR 966 (884) million, and the average market growth was 9%.

The most important individual therapy area for Orion is the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs continued to grow and clearly faster than the market as a whole in Japan. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending June 2010, total sales of Orion’s Parkinson’s drugs were up by 8% at USD 181 (167) million in the United States, up by 6% at a total of EUR 154 (145) million in the five largest Parkinson’s drugs markets in Europe, and up by 42% at EUR 39 (27) million in Japan. The market share of Orion’s Parkinson’s drugs was 18% in the United States, on average 16% in the five largest European markets and 9% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of the intensive care sedative Precedex (dexmedetomidine), which is becoming increasingly important for Orion, were up by 68% at USD 133 million in the 12-month period ending June 2010 (USD 79 million in the previous 12-month period); 85% of the sales were in the United States, where Precedex sales grew by 72% to USD 113 (66) million.

 

Published 10 August 2010

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–June 2010 totalled EUR 937 (960) million, down by 3% on the comparative period of the previous year. The market as a whole decreased most in pharmaceuticals covered by the reference price system, which has been in force since the beginning of April 2009.

Finland is the most important individual market for Orion, generating one-quarter of the Group’s net sales. Orion continued to strengthen its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2010 amounted to EUR 92 (91) million, up by one per cent on the comparative period. Orion’s market share was 10% (10%), which was nearly four percentage points higher than for the second-largest company.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2010 the total sales of Parkinson’s drugs in the United States were up by 6% at USD 1,026 million (USD 966 million in the previous 12-month period). The five largest European markets for Parkinson’s drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in March 2010 totalled EUR 937 (877) million, and the average market growth was 7%.

The most important individual therapy area for Orion is the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs continued to grow and clearly faster than the market as a whole in the United States and Japan. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending March 2010, total sales of Orion’s Parkinson’s drugs were up by 10% at EUR 179 (163) million in the United States, up by 6% at a total of EUR 152 (143) million in the five largest Parkinson’s drugs markets in Europe, and up by 48% at EUR 35 (24) million in Japan. The market share of Orion’s Parkinson’s drugs was 17% in the United States, on average 16% in the five largest European markets and 9% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of the intensive care sedative Precedex (dexmedetomidine), which is becoming increasingly important for Orion, were up by 55% at USD 101 million in 2009 (USD 65 million in 2008); 85% of the sales were in the United States, where Precedex sales grew by 62% to USD 85 (53) million.

 

Published 27 April 2010

Finland is the most important individual market for Orion, generating one-quarter of the Group’s net sales. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–March 2010 totalled EUR 464 million, down by 0.5% on the comparative period of the previous year. The market as a whole decreased most in pharmaceuticals covered by the reference price system, which has been in force since the beginning of April 2009.

Orion continued to strengthen its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–March 2010 amounted to EUR 47 million, up by 4%. Orion’s market share exceeded the ten per cent threshold, reaching 10.2% (9.7%), which was nearly four percentage points higher than for the second-largest company.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in 2009 the total sales of Parkinson’s drugs in the United States came to USD 1,000 million (USD 1,020 million in 2008), which is 2% less than in the previous year. The five largest European markets for Parkinson’s drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in 2009 totalled EUR 909 (868) million, and the average market growth was 5%.

Sales of Orion’s Parkinson’s drugs continued to grow clearly faster than the market as a whole. According to IMS Health pharmaceutical sales statistics, in 2009 total sales of Orion’s Parkinson’s drugs were up by 13% at EUR 499 (433) million.

According to statistics, sales of Orion’s Parkinson’s drugs in 2009 were up by 10% at USD 175 (159) million in the United States. In the five largest Parkinson’s drugs markets in Europe, sales of Orion’s Parkinson’s drugs were up by 6% at a total of EUR 150 (141) million. In Japan, sales of Orion’s Parkinson’s drugs were up by 77% at EUR 33 (19) million. The market share of Orion’s Parkinson’s drugs was 17% in the United States, an average of 16% in the five largest markets in Europe and 8% in Japan.